Autoimmune disease is one of the largest bodies of controlled research in cell therapy.
Mesenchymal stem cells are studied in autoimmune conditions for a specific reason: their documented interaction with immune signaling. That mechanism has now been examined across dozens of randomized controlled trials in conditions including rheumatoid arthritis, lupus, inflammatory bowel disease, and ankylosing spondylitis.
This page covers what those trials report, where the evidence is thinner, and what a serious review of your case looks at before anything is recommended.
Aurenza does not claim that regenerative medicine treats, cures, or reverses any autoimmune condition.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What the Research Shows
Autoimmune disease is where the cell therapy field has accumulated one of its largest bodies of controlled research, because MSCs are studied precisely for their documented interaction with immune signaling.
A 2022 systematic review and meta-analysis in Stem Cells International pooled 18 randomized controlled trials across five autoimmune diseases. For rheumatoid arthritis, included trials reported reduced disease activity and improved DAS28 scores, with regulatory T cells rising and inflammatory Th17 cells falling in responders. For lupus, pooled data showed improvement in SLEDAI disease activity, urine protein, and complement C3. For ankylosing spondylitis, treatment was associated with higher response rates and reductions in inflammatory markers. The scale of this literature keeps growing: a 2025 meta-analysis in Stem Cell Research and Therapy pooled 42 randomized trials covering 2,183 participants and concluded MSC transplantation may improve outcomes in spondyloarthritis, rheumatoid arthritis, and primary Sjogren's syndrome.
The individual trials underneath those numbers are real and traceable. A multicentre, randomised, placebo-controlled phase Ib/IIa trial in Annals of the Rheumatic Diseases studied intravenous expanded adipose-derived cells in refractory rheumatoid arthritis. A multicenter study in Arthritis Research and Therapy (2014) followed 40 patients with active, refractory lupus across four centers after umbilical cord MSC infusions: treatment was well tolerated with no transplantation-related adverse events, disease activity scores fell significantly at every follow-up through 12 months, and 24-hour proteinuria declined in lupus nephritis patients, building on the original severe-refractory-lupus work in Arthritis and Rheumatism (2010). And in inflammatory bowel disease, the evidence reaches a regulatory milestone covered on our gastrointestinal page: a stem cell therapy approved in the EU, UK, Switzerland, Israel, and Japan for a defined complication of Crohn's disease.
The Honest Line
Autoimmune disease is a category, not a condition, and the evidence is uneven inside it. Rheumatoid arthritis, lupus, and spondyloarthritis carry the most randomized data; other autoimmune conditions have far less, and the reviews themselves note variable cell sources, doses, and trial designs across studies. No study shows a guarantee it works every time, or that it will work for you, and every trial above studied cells alongside standard therapy, never as a replacement for the treatment plan your rheumatologist or gastroenterologist has built.
Why This Is Exactly Where a Candidacy Review Comes In
Which specific diagnosis you carry, how active it is right now, and what you are already taking determine whether any of this evidence speaks to your case, and those are exactly the inputs a review is built on. Every trial above produced its results in selected patients who met specific criteria. That is the gap between "documented in research" and "right for you," and it is the gap a candidacy review exists to close. Before anything is recommended, your bloodwork, biomarkers, imaging, and history are reviewed by a physician panel to establish whether you are actually in the population the research describes. If the picture supports moving forward, you will know exactly why. If it does not, you will be told that, plainly. That is where to start.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What Your Candidacy Review Covers
Your specific diagnosis and its current activity, documented by your specialist's notes and recent labs rather than symptoms alone.
Your inflammatory markers, which describe the environment any protocol would enter.
Your current medications, including biologics and immunosuppressants, and how your case is currently controlled.
Your organ involvement and complications, which change the risk calculus entirely.
Your bloodwork and biomarker panel, reviewed by a physician panel with specialist input where the case calls for it.
What to Ask Any Provider
Which trials in my specific condition are you relying on, and does my disease activity match the patients they enrolled? How will this interact with my current medications, and have you coordinated with my treating specialist? What is being administered, from what source, at what verified cell count? What would make me a poor candidate? What happens to my existing treatment plan?
The Honest Limits
Individual results cannot be predicted or guaranteed. These applications are not FDA approved for autoimmune conditions, and the procedure takes place in Mexico under COFEPRIS regulation. Never stop or change prescribed immunosuppressive or biologic therapy except under the direction of your treating specialist.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
Free consultation with a care consultant, many of whom are registered nurses. No sales reps. No receptionist.